Suppr超能文献

急性肾损伤:泌尿外科患者治疗中新型生物标志物及潜在应用。

Acute kidney injury: novel biomarkers and potential utility for patient care in urology.

机构信息

Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.

出版信息

Urology. 2011 Jan;77(1):5-11. doi: 10.1016/j.urology.2010.05.004.

Abstract

Urologists are integrally involved in the management of acute kidney injury (AKI), which is common after renal surgery or secondary to postrenal (obstructive) etiologies. The measurement of serum creatinine is a suboptimal indicator of AKI because it lags behind acute changes in renal function. Recent advances indicate that serum/urine biomarkers will prove useful for early detection of AKI, analogous to the use of cardiac enzymes for acute myocardial infarction. These serum/urine markers may guide future therapy, facilitate research efforts to reduce the severity of AKI, such as after partial nephrectomy, and allow for more accurate prognostication for patients with AKI.

摘要

泌尿科医生在急性肾损伤(AKI)的治疗中起着重要作用,这种损伤在肾手术后或继发于后肾(梗阻性)病因时很常见。血清肌酐的测量并不是 AKI 的最佳指标,因为它落后于肾功能的急性变化。最近的进展表明,血清/尿液生物标志物将有助于早期发现 AKI,类似于使用心肌酶检测急性心肌梗死。这些血清/尿液标志物可能指导未来的治疗,促进减少肾部分切除术后 AKI 严重程度的研究工作,并为 AKI 患者提供更准确的预后。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验